LOI Deadline
Posted: 3/26/2024

Congressionally Directed Medical Research Programs (CDMRP) -- Lung Cancer Research Program -- Concept Award

The intent of the FY24 LCRP Concept Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications in lung cancer. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Research applications only in the area of mesothelioma will not be accepted.

Inclusion of preliminary data is not required but is allowed. The strength of the proposed research should be based on sound scientific rationale and logical reasoning. The presentation of substantial preliminary data suggests that the proposed research project would be more appropriately submitted to a different FY24 LCRP funding opportunity. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Absence of preliminary data will not negatively affect scientific or programmatic review of the application.

Care Delivery and Health Disparity Option: The FY24 LCRP Concept Award mechanism encourages applications that specifically address the comprehensive lung cancer care and/or health disparities FY24 LCRP Areas of Emphasis by offering a Care Delivery and Health Disparity option. Applications from the Care Delivery and Health Disparity option will be peer and programmatically reviewed separately from applications submitted to the Cancer Research Continuum option.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their Families. Relevance to military health will be considered in determining relevance to the mission of the Defense Health Program (DHP) and FY24 LCRP during programmatic review.


  • REQUIRED Pre-Application Submission Deadline:  May 28, 2024
  • Application Submission Deadline: June 17, 2024
Areas of Interest

To meet the intent of the funding opportunity, all applications must address at least one Area of Emphasis in a way that can lead to, or directly effect, a breakthrough and have a major impact. The LCRP developed a strategy to address multiple issues in lung cancer research over the cancer continuum of care spectrum that will be considered for funding under the LCRP. These Areas of Emphasis are critical gaps in cancer research, care, and/or patient outcomes that, if addressed will lead to reduced suffering from lung cancer and improved quality of life of Service Members, Veterans, and the general public. Simply identifying an Area of Emphasis is not sufficient.

• Care Delivery and Health Disparity Option:
o Health Outcomes and Survivorship
Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on patients, families, and support systems with respect to the impact on quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer.
o Disparities
Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.

• Cancer Research Continuum Option:
o Biology and Etiology
Understand the molecular mechanisms of initiation and progression to lung cancer.
Understand contributors to lung cancer development other than tobacco.
Understand the biology of metastatic/oligometastatic disease progression.
o Prevention
Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries.
Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
o Detection, Diagnosis, and Surveillance
Improve and expand approaches to screening and early detection of lung cancer.
Identify strategies for prompt detection and/or characterization of progressive disease.
o Treatment and Prognosis
Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
Develop or optimize biomarkers to assist with therapeutic decision-making.
Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.

Eligibility Requirements

All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.
An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY24 LCRP Concept] Award should not exceed $120,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.